- Home
- ECX vs CLLS Comparison
ECX vs CLLS Comparison
Compare ECX & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ECX | CLLS |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | United Kingdom | France |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.6M | 394.4M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ECX | CLLS |
|---|---|---|
| Price | $1.04 | $3.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | ★ 655.5K | 17.2K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $819.14 | N/A |
| Revenue Next Year | $32.36 | $0.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $2.35 |
| 52 Week High | $2.70 | $5.48 |
Technical Indicators
Market Signals| Indicator | ECX | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 49.51 | 60.94 |
| Support Level | $0.99 | $3.41 |
| Resistance Level | $1.13 | $4.24 |
| Average True Range (ATR) | 0.05 | 0.14 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 62.96 | 81.25 |
Price Performance
Historical ComparisonAbout ECX ECARX Holdings Inc. Ordinary shares
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the Peoples Republic of China. The companies core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.